title: A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.
abstract: OBJECTIVE
  Topotecan is an established topoisomerase I inhibitor for the treatment of relapsed ovarian cancer. Myelotoxicity and suboptimal patient convenience associated with daily topotecan, however, have prompted investigators to explore alternate regimens, including a weekly regimen of topotecan. The objective of this study was to determine the maximum tolerated dose (MTD) of topotecan given as a weekly bolus in previously treated ovarian cancer patients.
  
  
  METHODS
  Second- and third-line ovarian cancer patients with measurable disease or elevated cancer antigen 125 received weekly bolus topotecan intravenously starting at 1.5 mg/m(2). Topotecan was escalated in dose increments of 0.5 mg/m(2) every 21 days as tolerability allowed. Dose-limiting toxicity was defined as grade 3/4 neutropenia or thrombocytopenia.
  
  
  RESULTS
  Thirty-two of 35 patients were evaluable for safety and tolerability. No notable toxicity was observed with weekly topotecan doses < 4 mg/m(2). Additionally, there was an absence of dose-limiting myelotoxicity and thrombocytopenia with weekly topotecan. The MTD of weekly topotecan without the use of granulocyte colony-stimulating factor support was 4 mg/m(2), with grade 2 anemia, chronic fatigue, and grade 2 gastrointestinal toxicity limiting further dose escalation. Weekly topotecan also demonstrated antitumor activity at doses >2 mg/m(2).
  
  
  CONCLUSIONS
  The establishment of a well-tolerated, weekly regimen of topotecan (4 mg/m(2), with a maximum recommended dose of 6 mg/m(2)) provides the basis for further investigation in phase II studies of single-agent and combination regimens in previously treated ovarian cancer patients.
authors.affiliation: Brookview Research, Inc., Nashville, Tennessee 37203, USA. hdh@us.inter.net
authors.forename: H D
authors.initials: HD
authors.lastname: Homesley
authors.forename: D J
authors.initials: DJ
authors.lastname: Hall
authors.forename: D A
authors.initials: DA
authors.lastname: Martin
authors.forename: G S
authors.initials: GS
authors.lastname: Lewandowski
authors.forename: L
authors.initials: L
authors.lastname: Vaccarello
authors.forename: W A
authors.initials: WA
authors.lastname: Nahhas
authors.forename: C L
authors.initials: CL
authors.lastname: Suggs
authors.forename: R G
authors.initials: RG
authors.lastname: Penley
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D019772:Topotecan / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019772:Topotecan